<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39446203</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1613-7671</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Wiener klinische Wochenschrift</Title><ISOAbbreviation>Wien Klin Wochenschr</ISOAbbreviation></Journal><ArticleTitle>Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency : A prospective controlled open-label trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00508-024-02459-6</ELocationID><Abstract><AbstractText>Impaired immune response to COVID-19 (coronavirus disease 2019) vaccination has been reported in patients with inborn errors of immunity (IEI). Repetitive vaccinations are recommended for this vulnerable group. Due to the high diversity within IEI patients, additional safety and immunogenicity data are needed to better understand these aspects especially in less common immunodeficiency syndromes. In this prospective open-label clinical trial, we assessed the humoral immune response and the T‑cell response in patients with IEI or severe MBL (mannose-binding lectin) deficiency (IEI/MBLdef) after three vaccinations. A total of 16 patients and 16 matched healthy controls (HC) with suboptimal humoral response defined by anti-SARS-CoV‑2 RBD (severe acute respiratory syndrome coronavirus type 2 receptor binding domain) antibodies below 1500 BAU/ml (binding antibody units per ml) after the second COVID-19 vaccination were enrolled in this study and qualified for a third mRNA vaccine dose. After 4 weeks following vaccination, 100% of HC and 75% of IEI/MBLdef patients exhibited anti-SARS-CoV‑2 RBD antibodies &gt; 1500 BAU/ml, although the difference was not statistically significant (75% vs. 100%; p = 0.109). Although post-vaccination IEI/MBLdef patients demonstrated significantly increased anti-SARS-CoV‑2 RBD antibodies and neutralizing antibodies compared to baseline, these responses were significantly lower in IEI/MBLdef patients compared to HCs. Notably, the third vaccination augmented the cellular immune response to both wild-type and omicron peptide stimulation. No serious adverse events were reported within the 4‑week follow-up period and, importantly, vaccination had little to no effect on the long-term disease activity and fatigue. This trial strongly supports the recommendation of repeated COVID-19 vaccinations for patients suffering from immunodeficiencies, especially when they exhibit an initially limited response to the vaccine.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vossen</LastName><ForeName>Matthias G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Infection Medicine, Medical University of Vienna, Austria (CCIM), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kartnig</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mrak</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simader</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stiasny</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Virology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kain</LastName><ForeName>Renate</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical University of Vienna, Clinical Institute for Pathology, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkmann</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Institute for Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haslacher</LastName><ForeName>Helmuth</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Institute for Laboratory Medicine, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aberle</LastName><ForeName>Judith H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Center for Virology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heinz</LastName><ForeName>Leonhard X</ForeName><Initials>LX</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sieghart</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgmann</LastName><ForeName>Heinz</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Department of Medicine I, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Infection Medicine, Medical University of Vienna, Austria (CCIM), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aletaha</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheinecker</LastName><ForeName>Clemens</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonelli</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Göschl</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-0948-9047</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. lisa.goeschl@meduniwien.ac.at.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Comprehensive Center for Inflammation and Immunity, Medical University of Vienna, Austria (CCII), Vienna, Austria. lisa.goeschl@meduniwien.ac.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>Wien Klin Wochenschr</MedlineTA><NlmUniqueID>21620870R</NlmUniqueID><ISSNLinking>0043-5325</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common variable immunodeficiency</Keyword><Keyword MajorTopicYN="N">Hypogammaglobulinemia</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Mannose-binding lectin</Keyword><Keyword MajorTopicYN="N">Primary immunodeficiency disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39446203</ArticleId><ArticleId IdType="doi">10.1007/s00508-024-02459-6</ArticleId><ArticleId IdType="pii">10.1007/s00508-024-02459-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fernandes Q, Inchakalody VP, Merhi M, Mestiri S, Taib N, El-Ella MAD, et al. Emerging COVID-19 variants and their impact on SARS-coV‑2 diagnosis, therapeutics and vaccines. Ann Med. 2022;54(1):524–40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2031274</ArticleId><ArticleId IdType="pubmed">35132910</ArticleId><ArticleId IdType="pmc">8843115</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai V, Nathan A, Kaseke C, Berrios C, Khatri A, Choi S, et al. T cell reactivity to the SARS-coV‑2 omicron variant is preserved in most but not all individuals. Cell. 2022;185(6):1041–1051 e6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.029</ArticleId><ArticleId IdType="pubmed">35202566</ArticleId><ArticleId IdType="pmc">8810349</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. 2022;42(7):1473–507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01289-3</ArticleId><ArticleId IdType="pubmed">35748970</ArticleId><ArticleId IdType="pmc">9244088</ArticleId></ArticleIdList></Reference><Reference><Citation>Deya-Martinez A, Garcia-Garcia A, Gonzalez-Navarro EA, Yiyi L, Vlagea A, Jordan I, et al. COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era. Clin Immunol. 2021;230:108821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108821</ArticleId><ArticleId IdType="pubmed">34391937</ArticleId><ArticleId IdType="pmc">8359496</ArticleId></ArticleIdList></Reference><Reference><Citation>Goudouris ES, Pinto-Mariz F, Mendonca LO, Aranda CS, Guimaraes RR, Kokron C, et al. Outcome of SARS-coV‑2 infection in 121 patients with inborn errors of immunity: a cross-sectional study. J Clin Immunol. 2021;41(7):1479–89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01066-8</ArticleId><ArticleId IdType="pubmed">34164762</ArticleId><ArticleId IdType="pmc">8221557</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. J Allergy Clin Immunol. 2021;147(2):520–31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.09.010</ArticleId><ArticleId IdType="pubmed">32980424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bez P, D’Ippolito G, Deiana CM, Finco Gambier R, Pica A, Costanzo G, et al. Struggling with COVID-19 in adult inborn errors of immunity patients: a case series of combination therapy and multiple lines of therapy for selected patients. Life. 2023;13(7).</Citation></Reference><Reference><Citation>McDonnell J, Cousins K, Younger MEM, Lane A, Abolhassani H, Abraham RS, et al. COVID-19 vaccination in patients with inborn errors of immunity reduces hospitalization and critical care needs related to COVID-19: a USIDNET report. J Clin Immunol. 2024;44(4):86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-023-01613-5</ArticleId><ArticleId IdType="pubmed">38578389</ArticleId><ArticleId IdType="pmc">10997719</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen LPM, Grobben M, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, et al. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program. Front Immunol. 2024;15:1390022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1390022</ArticleId><ArticleId IdType="pubmed">38698851</ArticleId><ArticleId IdType="pmc">11063285</ArticleId></ArticleIdList></Reference><Reference><Citation>Aberumand B, Goulstone AW, Betschel S. Understanding attitudes and obstacles to vaccination against COVID-19 in patients with primary immunodeficiency. Allergy Asthma Clin Immunol. 2022;18(1):38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13223-022-00679-x</ArticleId><ArticleId IdType="pubmed">35534860</ArticleId><ArticleId IdType="pmc">9083475</ArticleId></ArticleIdList></Reference><Reference><Citation>Pergent M, Haerynck F, Hoste L, Gardulf A. COVID-19 vaccination in patients with primary immunodeficiencies: an international survey on patient vaccine hesitancy and self-reported adverse events. Front Immunol. 2023;14:1166198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1166198</ArticleId><ArticleId IdType="pubmed">37143673</ArticleId><ArticleId IdType="pmc">10151802</ArticleId></ArticleIdList></Reference><Reference><Citation>Goschl L, Mrak D, Grabmeier-Pfistershammer K, Stiasny K, Haslacher H, Schneider L, et al. Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency. Front Immunol. 2022;13:974987.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.974987</ArticleId><ArticleId IdType="pubmed">36189225</ArticleId><ArticleId IdType="pmc">9515892</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmettler S, DiGiacomo DV, Yang NJ, Lam T, Naranbhai V, Dighe AS, et al. Response to severe acute respiratory syndrome coronavirus 2 initial series and additional dose vaccine in patients with predominant antibody deficiency. J Allergy Clin Immunol Pract. 2022;10(6):1622–1634 e4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2022.03.017</ArticleId><ArticleId IdType="pubmed">35381395</ArticleId><ArticleId IdType="pmc">8976568</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponsford MJ, Evans K, Carne EM, Jolles S, Immunodeficiency Centre for W, Division of Population M. COVID-19 vaccine uptake and efficacy in a national immunodeficiency cohort. J Clin Immunol. 2022;42(4):728–31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01223-7</ArticleId><ArticleId IdType="pubmed">35149962</ArticleId><ArticleId IdType="pmc">8853337</ArticleId></ArticleIdList></Reference><Reference><Citation>Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, et al. Humoral and cellular response following vaccination with the BNT162b2 mRNA COVID-19 vaccine in patients affected by primary immunodeficiencies. Front Immunol. 2021;12:727850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.727850</ArticleId><ArticleId IdType="pubmed">34671350</ArticleId><ArticleId IdType="pmc">8521226</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, et al. Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. J Allergy Clin Immunol. 2022;149(6):1949–57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.04.002</ArticleId><ArticleId IdType="pubmed">35421449</ArticleId><ArticleId IdType="pmc">8996444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham MN, Murugesan K, Banaei N, Pinsky BA, Tang M, Hoyte E, et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B‑cell defects. J Allergy Clin Immunol. 2022;149(3):907–911 e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.11.022</ArticleId><ArticleId IdType="pubmed">34952033</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D, Mu X, Duque JSR, Cheng SMS, Wang M, Zhang W, et al. Safety and immunogenicity of 3 doses of BNT162b2 and coronaVac in children and adults with inborn errors of immunity. Front Immunol. 2022;13:982155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.982155</ArticleId><ArticleId IdType="pubmed">36203563</ArticleId><ArticleId IdType="pmc">9530261</ArticleId></ArticleIdList></Reference><Reference><Citation>Milito C, Cinetto F, Garzi G, Palladino A, Puca M, Brambilla E, et al. Safety of mRNA COVID-19 vaccines in patients with inborn errors of immunity: an Italian multicentric study. J Clin Immunol. 2022; 1–9.</Citation></Reference><Reference><Citation>Goda V, Krivan G, Kulcsar A, Gonczi M, Tasnady S, Matula Z, et al. Specific antibody and the T‑cell response elicited by BNT162b2 boosting after two ChAdox1 ncoV-19 in common variable immunodeficiency. Front Immunol. 2022;13:907125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.907125</ArticleId><ArticleId IdType="pubmed">35784359</ArticleId><ArticleId IdType="pmc">9247171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauerwein KMT, Geier CB, Stemberger RF, Rossmanith R, Akyaman H, Illes P, et al. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders. J Allergy Clin Immunol. 2023;151(4):922–5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.11.013</ArticleId><ArticleId IdType="pubmed">36463978</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman O, Altman Doss AM, Kaplonek P, Liang CY, VanBlargan LA, Chen RE, et al. mRNA vaccine boosting enhances antibody responses against SARS-coV‑2 omicron variant in individuals with antibody deficiency syndromes. Cell Rep Med. 2022;3(6):100653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100653</ArticleId><ArticleId IdType="pubmed">35688161</ArticleId><ArticleId IdType="pmc">9179023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gernez Y, Murugesan K, Cortales CR, Banaei N, Hoyte L, Pinsky BA, et al. Immunogenicity of a third COVID-19 messenger RNA vaccine dose in primary immunodeficiency disorder patients with functional B‑cell defects. J Allergy Clin Immunol Pract. 2022;10(5):1385–1388 e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2022.02.030</ArticleId><ArticleId IdType="pubmed">35259538</ArticleId><ArticleId IdType="pmc">8897836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, et al. Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls. Ann Rheum Dis. 2022;.</Citation></Reference><Reference><Citation>Brandstetter C, Haller MC, Berger JM, Kerschner H, Apfalter P, Cejka D. Humoral response after a third and fourth dose of mRNA-based SARS-CoV‑2 vaccine in previously seronegative kidney transplant recipients. Wien Klin Wochenschr. 2022;134(23–24):815–21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00508-022-02103-1</ArticleId><ArticleId IdType="pubmed">36326920</ArticleId><ArticleId IdType="pmc">9632590</ArticleId></ArticleIdList></Reference><Reference><Citation>Das Barshan A, Matsumoto-Takahashi ELA. Efficacy of COVID-19 vaccines in patients with hematological malignancy compared to healthy controls: a systematic review and meta-analysis. JMA J. 2024;7(2):153–71.</Citation><ArticleIdList><ArticleId IdType="doi">10.31662/jmaj.2023-0171</ArticleId><ArticleId IdType="pubmed">38721084</ArticleId><ArticleId IdType="pmc">11074501</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrabba M, Baselli LA, Consonni D, Ceriotti F, Fabio G. Responses to SARS-coV‑2 vaccines of patients with common variable immune deficiencies and X-linked Agammaglobulinemia. J Clin Immunol. 2022;42(5):911–3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01251-3</ArticleId><ArticleId IdType="pubmed">35325341</ArticleId><ArticleId IdType="pmc">8944176</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdemiral C, Cevik NN, Yavuz G, Gormez O, Zengin AB, Esenboga S, et al. The spectrum of side effects associated with COVID-19 vaccines in patients with inborn errors of immunity. Clin Immunol. 2024;259:109878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2023.109878</ArticleId><ArticleId IdType="pubmed">38122840</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>